Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Decitabine - Janssen-Cilag/Otsuka Pharmaceutical

Drug Profile

Decitabine - Janssen-Cilag/Otsuka Pharmaceutical

Alternative Names: 127716; 2'-deoxy-5-azacytidine; 2353-33-5; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 5-aza-2'-deoxycytidine; DAC; Dacogen; Decitabine mesylate; Deoxycytidine; Dezocitidine; E 7373; NSC-127716

Latest Information Update: 15 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Indiana University; SuperGen
  • Developer Eisai Co Ltd; HOVON Foundation; Janssen-Cilag; M. D. Anderson Cancer Center; Otsuka Pharmaceutical; Sidney Kimmel Cancer Center; Xian-Janssen
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Sickle cell anaemia; Myelodysplastic syndromes; Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Phase I/II Malignant melanoma; Ovarian cancer
  • Phase I Solid tumours
  • Discontinued Colorectal cancer

Most Recent Events

  • 30 Sep 2019 Otsuka America Pharmaceutical re-initiates enrolment in a a phase I trial in Acute myeloid leukaemia (Combination therapy, Second-line therapy) in USA (IV) (NCT03063944)
  • 01 May 2019 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Combination therapy, Late-stage disease, Metastatic disease) in USA (PO) (NCT03875287)
  • 07 Nov 2018 Eisai terminates a phase I/II trial in Malignant melanoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, Combination therapy) in USA due to toxicity and lack of efficacy (IV) (NCT00791271)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top